CoChat

Safety and tolerability of sodium-glucose cotransporter-2 inhibitors in children and young adults: a systematic review and meta-analysis

Nagendra, Lakshmi, Dutta, Deep, Girijashankar, Harish Bukkasagar, Khandelwal, Deepak, Lathia, Tejal, Sharma, Meha · 2024 · Annals of Pediatric Endocrinology & Metabolism
Cited by 8

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Purpose: Sodium glucose cotransporter-2 inhibitors (SGLT2i) have been evaluated in children with type 2 diabetes mellitus (T2DM), type 1 diabetes mellitus (T1DM), and several other nondiabetic conditions. Potential tolerability issues have prevented the routine use of SGLT2i in children with diabetes. However, no meta-analysis to date has evaluated the safety and tolerability of SGLT2i in children. This systematic review and meta-analysis aimed to address this knowledge gap.Methods: Databases were searched for randomized controlled trials (RCTs), case control, and cohort studies involving children receiving SGLT2i in the intervention-arm. Primary outcome was occurrence of treatment emergent adverse events (TAEs). Secondary outcomes were evaluation of glycemic efficacy and occurrence of severe adverse events (SAEs), hypoglycemia, ketosis, genital or urinary infections, and any other adverse events.Results: From the 27 articles initially screened, data from 4 RCTs (258 children) were analyzed. In children with T2DM, occurrence of TAEs (odds ratio [OR], 1.77; 95% confidence interval [CI], 0.93–3.36; P=0.08; I2=0%), SAEs (OR, 0.45; 95% CI, 0.08–2.54; P=0.37; I2=0%), ketoacidosis (OR, 0.33; 95% CI, 0.01–8.37; P=0.50), urinary tract infections (OR, 2.34; 95% CI, 0.44–12.50; P=0.32; I2=0%), and severe hypoglycemia (OR, 4.47; 95% CI, 0.21–96.40; P=0.34) were comparable among the SGLTi group and placebo. Compared to placebo, T2DM children receiving SGLTi had significantly lower glycosylated hemoglobin at 24–26 weeks (mean difference [MD], -0.79%; 95% CI, -1.33 to -0.26; P=0.004; I2=0%). In T1DM children, β-hydroxybutyrate levels were significantly higher in the SGLTi group than the placebo group (MD, 0.11 mmol/L; 95% CI, 0.05–0.17; P=0.0005; I2=53%). In T1DM, there was not a single report of an SAE, ketoacidosis, or severe hypoglycemia in either the placebo or treatment groups, but time-in-range was considerably greater in the SGLT2i group than the placebo group (68%±6% vs. 50%±13%, P<0.001).Conclusion: SGLT2i use in children and young adults appears to be both safe and tolerable based on our meta-analyses and review of the literature.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.6065/apem.2346162.081

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 31

  1. 2023, FDA approves new class of medicines to treat pediatric type 2 diabetes [Internet]
  2. 10.1001/jamanetworkopen.2022.47186 · DOI
  3. 10.1016/j.pcd.2022.09.006 · DOI
  4. Phillip, 2021, Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52-week outcomes from the DEPICT-1 and -2 studies, 549
  5. Mathieu, 2020, Benefit/risk profile of dapagliflozin 5 mg in the DEPICT-1 and -2 trials in individuals with type 1 diabetes and body mass index ≥27 kg/m2, 2151
  6. 10.1159/000519613 · DOI
  7. 10.1542/peds.2021-055671 · DOI
  8. Grünert, 2022, Efficacy and safety of empagliflozin in glycogen storage disease type Ib: Data from an international questionnaire, 1781
  9. 10.1515/jpem-2019-0389 · DOI
  10. 10.1007/s00246-022-02983-0 · DOI
  11. Cui, 2023, [Short-term efficacy of dapagliflozin in children with hereditary proteinuric kidney disease], 164
  12. 10.1136/bmj.d5928 · DOI · Paper page
  13. 10.1016/j.dsx.2020.08.039 · DOI
  14. 10.3803/enm.2020.818 · DOI · Paper page
  15. 10.1136/bmj.b2700 · DOI · Paper page
  16. Laffel, 2023, Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial, 169
  17. 10.1016/s2213-8587(22)00052-3 · DOI
  18. Biester, 2021, Add-on therapy with dapagliflozin under full closed loop control improves time in range in adolescents and young adults with type 1 diabetes: The DAPADream study, 599
  19. Biester, 2017, Effects of dapagliflozin on insulin-requirement, glucose excretion and β-hydroxybutyrate levels are not related to baseline HbA1c in youth with type 1 diabetes, 1635
  20. 10.1111/dme.13629 · DOI
  21. 10.1111/dom.12638 · DOI
  22. 10.1186/s13023-022-02345-2 · DOI
  23. 10.2169/internalmedicine.9632-22 · DOI
  24. 10.1186/s12902-021-00802-w · DOI
  25. 10.3389/fendo.2022.897776 · DOI
  26. Scirica, 2015, Heart failure, saxagliptin, and diabetes mel litus : obs er v at ions f rom t he S AVOR- TI MI 53 randomized trial, e198
  27. 10.1297/cpe.2023-0007 · DOI
  28. 2024, 14, S258
  29. 10.5694/mja2.50666 · DOI
  30. Ong Lopez, 2024, Efficacy of sodium glucose cotransporter 2 inhibitors on hepatic fibrosis and steatosis in non-alcoholic fatty liver disease: an updated systematic review and meta-analysis, 2122
  31. 10.1038/s41569-020-0406-8 · DOI · Paper page

Cited by

See all 8

Metadata

Authors
Nagendra, L., Dutta, D., Girijashankar, H. B., Khandelwal, D., Lathia, T., & Sharma, M.
Venue
Annals of Pediatric Endocrinology & Metabolism
Published
2024-04-30
Volume
29
Issue
2
Pages
82-89
ISSN
  • 2287-1012
  • 2287-1292
Cited by
8
References
4
Language
en
Licence
creativecommons.org/licenses/by-nc/4.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.